Australia markets closed

Clarus Therapeutics Holdings, Inc. (CRXT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.3914-0.0236 (-5.69%)
At close: 04:00PM EDT
0.4100 +0.02 (+4.75%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.4150
Open0.4106
Bid0.4000 x 800
Ask0.4099 x 2200
Day's range0.3801 - 0.4200
52-week range0.3300 - 31.2400
Volume2,709,837
Avg. volume14,006,701
Market cap20.361M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.8000
Earnings date16 May 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.63
  • GlobeNewswire

    Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting

    JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., June 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new data for JATENZO (testosterone undecanoate) will be

  • GlobeNewswire

    Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)

    JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent in FDA’s Orange Book, which would bring the total number of Orange Book-listed patents covering JATENZO to eight NORTHBROOK, Ill., May 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical ne

  • GlobeNewswire

    Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results

    First quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK, Ill., May 16, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women,